A 5062
Requires health insurance and Medicaid coverage for testing and treatments to slow progression of Alzheimer's disease and related disorders.
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed General Assembly
- Passed Senate
- To Governor
- Became Law
Bill overview
This bill requires New Jersey’s health insurance plans and Medicaid to cover diagnostic testing and FDA-approved medications that can slow the progression of Alzheimer’s disease and related disorders. It ensures that these treatments are accessible to patients without requiring ‘step therapy,’ which often delays access to necessary medications. The bill aims to improve care for individuals affected by these conditions and potentially reduce long-term healthcare costs by delaying the need for more intensive care settings. It expands coverage for medications currently not included in state programs.
Sponsors
Official sponsors from legislative records.
Primary sponsors
Cosponsors
Anthony Angelozzi
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.